Prior to the ICER meeting to review evidence and vote on cost-effectiveness ratings for NSCLC treatments, five prominent oncologists...

I have extensive experience in “real world” policy-setting and decision-making and I am puzzled about the motivations regarding the...

McGivney Global Advisors publishes quarterly reports  assessing the changes and impact of Oncology Value Metrics, including NCCN Evidence...

Will a spate of recent lawsuits shift the balance of power in the health care industry? While no companies in the health care industry...

A McGivney Global Advisors op-ed on Oncology Value Metrics and ICER was referenced by the Biotechnology Industry Organization, quoting...